Every regulated or semi-regulated industry eventually faces the same structural problem: the rules are still being written while the business is already operating. Cannabis wholesalers dealt with it for years. Vape suppliers deal with it now. Botanical wellness manufacturers, including the growing kratom industry, are working through the same challenge in real time — trying to build durable B2B relationships in a category where the regulatory floor shifts state by state and, occasionally, month by month.
What’s striking about these industries is how much more the wholesale relationship matters compared to more conventional B2B categories. In a stable, well-regulated industry, a retailer can source from several interchangeable suppliers and switch fairly easily if pricing or service falls short. In a category still finding its regulatory footing, switching suppliers isn’t just a pricing decision — it’s a compliance decision. A retailer who partners with a wholesaler that maintains rigorous lab testing, consistent batch documentation, and a track record of transparent sourcing is buying more than product; they’re buying a degree of protection against the reputational and legal risk that comes with operating in a gray-area category.
That dynamic has pushed B2B relationships in these industries to look less like transactional supply deals and more like long-term partnerships. Retailers want suppliers who will still be operating, and still be reachable, the next time a state updates its regulations or a payment processor tightens its policies. Wholesalers, in turn, have an incentive to over-invest in the kind of documentation and quality control that wouldn’t be strictly necessary in a fully mature, uniformly regulated market — because that documentation is often the thing standing between a retailer’s shelf space and a compliance headache down the line.
Kingdom Kratom is a useful example of how this plays out on the ground. As a manufacturer and wholesaler operating in a category that state legislatures are still actively debating, the business has had to build its retailer relationships around the same fundamentals that matter in any regulated B2B niche: consistent lab testing, clear batch tracking, and enough operational transparency that a retail partner can answer questions from their own local regulators without having to guess. That kind of infrastructure isn’t just good practice — in categories like this one, it’s often the deciding factor in which suppliers retailers are willing to build a long-term relationship with at all.
There’s a broader lesson here for anyone studying how regulated-adjacent industries mature. The businesses that survive the early, ambiguous phase of a category’s regulatory life tend to be the ones that treated compliance as a competitive advantage rather than a cost center from the very beginning. A supplier who waits for a state to mandate lab testing before doing it voluntarily is always going to be playing catch-up against one who built that testing into their process from day one. Retailers notice this, and in a category where trust is scarce and reputational risk runs both directions, that head start compounds.
It’s also worth noting how this affects deal structure and negotiation. Wholesale agreements in these industries increasingly include provisions that would be unusual in more conventional B2B contracts — documentation-sharing clauses, right-to-audit language, and contingency plans for how both parties will respond if a jurisdiction changes its rules mid-contract. That level of specificity reflects a simple reality: in an industry where the ground can shift under both parties with little warning, a wholesale relationship built purely on price is a fragile one.
The broader pattern extends well beyond botanicals. Any founder or retailer operating in a category still awaiting regulatory clarity — whether that’s certain supplement classes, novel beverage ingredients, or other emerging wellness products — is essentially running the same playbook: find suppliers who treat transparency as infrastructure, not marketing, and build relationships sturdy enough to survive rule changes neither party controls. The industries that get this right end up with something more valuable than a favorable price on this quarter’s order. They end up with the kind of supplier trust that keeps a business operating through the exact regulatory uncertainty that sinks less disciplined competitors.
